Actionable offering helps enable earlier, more personalized breast cancer interventions
BOSTON, SALT LAKE CITY, and FULTON, MD — November 25, 2025 — Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens
The agreement brings together three leaders in breast cancer:
Clairity – developer of Clairity Breast, the first and only FDA-authorized offering to estimate a woman’s five-year breast cancer risk directly from a routine mammogram
Myriad Genetics – a leader in molecular diagnostic testing and precision medicine, offering the MyRisk ® Hereditary Cancer Test with RiskScore ®, which combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk
MagView – a leader in comprehensive software solutions for breast imaging centers
For the first time, clinicians and patients will have access to an integrated view of genotype (Myriad’s MyRisk with RiskScore test) and phenotype (Clairity Breast) through MagView’s Luminary Risk platform, which supports breast cancer risk assessment programs across the United States.
“By integrating directly with MagView alongside Myriad, we are giving clinicians a more complete and actionable view of risk than can be achieved using age and family history alone,” said Jeff Luber, CEO, Clairity, “Using AI-powered risk assessment, Clairity Breast identifies women at the highest risk from a routine mammogram.”
“Effective screening of individuals with elevated risk of cancer is an important part of the cancer care continuum,” said Sam Raha, President and CEO, Myriad Genetics. “By pairing the MyRisk Hereditary Cancer Test with Clairity’s AI-powered risk assessment within MagView’s workflow, we aim to empower clinicians with actionable results, helping to enable earlier, more personalized interventions in the fight against breast cancer.”
“Our platform streamlines how risk information is captured, interpreted, and acted on,” said Bryan Chapin, President and CEO, MagView. “Integrating Clairity and MyRisk into one platform gives providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency.”